Related Experiment Video
Updated: Jun 14, 2025
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
Published on: July 18, 2017
Unlocking the Potential: FKK6 as a Microbial Mimicry-Based Therapy for Chronic Inflammation-Associated Colorectal
Abstract:
Chronic intestinal inflammation significantly contributes to the development of colorectal cancer (CRC) and remains a pertinent clinical challenge, necessitating novel therapeutic approaches. Indole-based microbial metabolite mimics FKK6, which is a ligand and agonist of the pregnane X receptor (PXR), was recently demonstrated to have PXR-dependent anti-inflammatory and protective effects in a mouse model of dextran sodium sulfate (DSS)-induced acute colitis. Here, we examined the therapeutic potential of FKK6 in a mouse model (C57BL/6 FVB humanized PXR mice) of colitis-associated colon cancer (CAC) induced by azoxymethane (AOM) and dextran sodium sulfate (DSS). FKK6 (2 mg/kg) displayed substantial anti-tumor activity, as revealed by reduced size and number of colon tumors, improved colon histopathology, and decreased expression of tumor markers (c-MYC, β-catenin, Ki-67, cyclin D) in the colon. In addition, we carried out the chronic toxicity (30 days) assessment of FKK6 (1 mg/kg and 2 mg/kg) in C57BL/6 mice. Histological examination of tissues, biochemical blood analyses, and immunohistochemical staining for Ki-67 and γ-H2AX showed no difference between FKK6-treated and control mice. Comparative metabolomic analyses in mice exposed for 5 days to DSS and administered with FKK6 (0.4 mg/kg) revealed no significant effects on several classes of metabolites in the mouse fecal metabolome. Ames and micronucleus tests showed no genotoxic and mutagenic potential of FKK6 in vitro . In conclusion, anticancer effects of FKK6 in AOM/DSS-induced CAC, together with FKK6 safety data from in vitro tests and in vivo chronic toxicity study, and comparative metabolomic study, are supportive of the potential therapeutic use of FKK6 in the treatment of CAC.
Insights
FKK6, a PXR agonist, demonstrated significant anticancer effects in a colitis-associated colon cancer mouse model. Chronic toxicity and genotoxicity studies confirmed FKK6
Area of Science:
- Gastroenterology and Hepatology
- Oncology
- Pharmacology
Background:
- Chronic intestinal inflammation is a major driver of colorectal cancer (CRC).
- Novel therapeutic strategies targeting inflammation-driven CRC are urgently needed.
- Pregnane X receptor (PXR) agonists, like indole metabolite FKK6, show anti-inflammatory potential.
Purpose of the Study:
- To evaluate the therapeutic efficacy of FKK6 in a mouse model of colitis-associated colon cancer (CAC).
- To assess the safety profile of FKK6 through chronic toxicity and genotoxicity studies.
Main Methods:
- Colitis-associated colon cancer (CAC) was induced in mice using azoxymethane (AOM) and dextran sodium sulfate (DSS).
- FKK6 treatment efficacy was assessed by tumor burden, histopathology, and tumor marker expression.
- Chronic toxicity, metabolomic, Ames, and micronucleus tests were performed to evaluate FKK6 safety.
Main Results:
- FKK6 significantly reduced colon tumor size and number, improved histopathology, and decreased tumor markers (c-MYC, β-catenin, Ki-67, cyclin D).
- No significant chronic toxicity or genotoxic/mutagenic potential was observed in FKK6-treated mice or in vitro tests.
- Metabolomic analysis showed no significant impact of FKK6 on the fecal metabolome.
Conclusions:
- FKK6 exhibits significant anticancer effects in a preclinical model of colitis-associated colon cancer.
- FKK6 demonstrates a favorable safety profile based on in vitro and in vivo studies.
- These findings support FKK6 as a potential therapeutic agent for treating CAC.
